For Healthcare Professionals

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

clipboard-pencil

About the study

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Fresh pre-treatment and on-treatment tumor biopsy must be provided for biomarker analysis
  2. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and at least 1 lesion accessible for biopsy. Fine needle biopsy, cytology, and bone lesion biopsies are not acceptable.
  3. Eastern Cooperative Oncology Group Performance Status of 0 or 1
  4. Radiographically documented progressive disease on or after the most recent therapy
  5. Received standard-of-care therapies, (except for Part 1C, where participants with prior docetaxel use for the advanced/metastatic setting will be excluded), including an available programmed death (ligand)-1 inhibitor known to be effective in the tumor type for which they are being evaluated
  6. Advanced or metastatic disease and have received, be refractory to, not be a candidate for, or be intolerant of existing therapies known to provide clinical benefit for the condition of the participant

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Women who are pregnant or breastfeeding
  2. Primary central nervous system (CNS) malignancy
  3. Untreated CNS metastases
  4. Leptomeningeal metastases
  5. Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment
  6. Active, known, or suspected autoimmune disease
  7. Condition requiring systemic treatment with either corticosteroids within 14 days or other immunosuppressive medications within 30 days of the first dose of study treatment
  8. Prior organ or tissue allograft
  9. Uncontrolled or significant cardiovascular disease
  10. Major surgery within 4 weeks of study drug administration
  11. History of or with active interstitial lung disease or pulmonary fibrosis

Other protocol-defined inclusion/exclusion criteria apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Cervical Cancer,Gastric/Gastroesophageal Junction Adenocarcinoma,Microsatellite Stable Colorectal Cancer,Non-Small-Cell Lung Cancer,Squamous Cell Carcinoma of Head and Neck,Carcinoma, Renal Cell,Urothelial Carcinoma,Pancreatic Adenocarcinoma,Melanoma,Ovarian Neoplasms,Triple Negative Breast Neoplasms

Age (in years)

18+

Phase

Phase 1/Phase 2

Participants needed

665

Est. Completion Date

Sep 15, 2026

Treatment type

Interventional


Sponsor

Bristol-Myers Squibb

ClinicalTrials.gov identifier

NCT04895709

Study number

CA052002

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.